Amgen Pushes to Unseal Regeneron-Viatris Eylea Case Filings

Amgen Inc. urged a federal judge to unseal scores of documents in Regeneron Pharmaceuticals Inc.’s patent-infringement suit over Viatris Inc.’s proposed biosimilar version of Eylea, saying the public has a right to access filings including “potentially dispositive allegations” that the patents are unenforceable.

Amgen asked Judge Thomas S. Kleeh to let it intervene in the case “for the limited purpose of unsealing certain judicial records (or portions thereof) currently unavailable to the public, in accordance with the public’s First Amendment and common law rights,” according to Amgen’s memorandum supporting its motion filed Tuesday in the US District Court for the ...